Dupixent COPD denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent copd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Dupixent for COPD

A prior-authorization (PA) denial means UnitedHealthcare did not receive — or did not find sufficient — pre-approval documentation before the prescription was dispensed or before the claim was processed. For a high-cost biologic like dupilumab in a relatively newer indication such as COPD, UHC virtually always requires PA. This is a process denial as much as a clinical one: it means documentation must be submitted to and approved by UHC's pharmacy or medical management team before coverage applies.

If prior authorization was attempted and denied on clinical grounds, the appeal process described below applies. If PA was never submitted, the first step is submitting one.

## Federal Appeal Rights

• ERISA §503 requires a full-and-fair internal review of any adverse benefit determination, including PA denials.
• ACA §2719 entitles you to external IRO review if the internal appeal is denied on clinical grounds — at no cost to you.
• Internal appeal: typically 180 days from the denial or PA denial notice.
• External review: typically 4 months from final internal denial.
• Expedited PA and expedited appeal: available when standard timelines would seriously jeopardize your health — request in writing with prescriber support.

## The Prior Authorization Submission Process

1. Your prescriber initiates PA — the PA request must come from the prescribing physician's office using UHC's current PA submission portal or fax process. Confirm the correct submission pathway with your prescriber. 2. Assemble clinical documentation — the PA package should include: diagnosis notes with COPD confirmation, type-2 inflammatory phenotype documentation (eosinophil or biomarker data), exacerbation history with dates, prior therapy history showing inadequate response to standard treatments, and a prescriber letter of medical necessity. 3. Reference UHC's PA criteria — obtain UnitedHealthcare's current PA criteria for dupilumab in COPD and confirm the submission addresses every listed requirement. The FDA-approved prescribing label should be referenced to confirm indication alignment. 4. Track the PA decision timeline — UHC is required to render a non-urgent PA decision within a specified timeframe (check your plan documents; typically 15 days for medical, 72 hours for urgent). Get the reference number for your submission.

## If PA Is Denied on Clinical Grounds

Proceed with a formal internal appeal. Gather:

• The written PA denial with the specific clinical criteria cited
• Prescriber medical-necessity letter addressing each denial reason
• Chart documentation mapped to every UHC criterion
• FDA prescribing label and applicable guideline organization references

## Criteria-Mapping Structure

| UHC PA Criterion | Documentation to Submit | |---|---| | COPD diagnosis confirmed | Spirometry, clinical notes, diagnosis code | | Type-2 inflammatory phenotype | Eosinophil/biomarker data in chart | | Prior standard therapy inadequate | Dated medication history with outcomes | | Prescriber attestation | Signed medical-necessity letter |

If UHC denies the internal appeal, escalate to IRO external review immediately.